HOME >> BIOLOGY >> NEWS
ANU scientists crack DNA replication mystery

A team of scientists led by Professor Nick Dixon at the Research School of Chemistry at The Australian National University have cracked one of the great DNA mysteries. For more than 20 years scientists have tried in vain to understand the last step in the copying of DNA in cells that are about to divide.

The research findings were published in the prestigious international journal Cell this morning.

In all cells, DNA is copied by a large molecular machine called the replisome. The replisome does two things: it pulls the two DNA strands apart, and then it makes copies of both of the strands at the same time. "You can think of the strand separation part like a snowplough. The replisome tracks along one of the DNA strands and pushes the other one off it," Professor Dixon said.

In certain bacteria, a small protein called TUS binds to the last part of DNA to be copied in a way that stops the replisome when it faces in one direction, but not in the other. How it can work this way has been a long standing puzzle.

The ANU team finally solved the important question of how TUS stops the replisome in this directional manner. "When the replisome comes along from one direction, separation of the two DNA strands simply knocks the TUS off as you'd expect. But when it comes from the other direction, the strand separation near TUS leads to one of the DNA bases flipping over and inserting itself like a key in a lock in a perfectly shaped pocket on the surface of TUS. TUS is locked onto the DNA and this stops the replisome snowplough in its tracks."

Professor Dixon said the discovery was important "not just because it solved a fundamental scientific question, but also because TUS was found to lock onto the DNA very strongly and in an entirely new way."

"Strong interactions like this have great potential to be used in bio- and nano-technology in fabricating new devices that might for example, be used for early detection of dis
'"/>

Contact: Jane O'Dwyer
61-26-125-5001
Research Australia
30-Jun-2006


Page: 1 2

Related biology news :

1. UK scientists working to help cut ID theft
2. Smithsonian scientists show differing patterns of rainforest biodiversity
3. Weizmann Institute scientists discover a control mechanism for metastasis
4. Cornell scientists link E. coli bacteria to Crohns disease
5. UCLA scientists produce functioning neurons from human embryonic stem cells
6. ASBMB taps 8 scientists and 1 politician for top awards
7. UF, French scientists seek test to detect gene doping in athletes
8. In a first, Einstein scientists discover the dynamics of transcription in living mammalian cells
9. Forsyth scientists gain new understanding of adult stem cell regulation
10. Nanotechnology helps scientists make bendy sensors for hydrogen vehicles
11. After a decades-long search, scientists identify new genetic risk factors for multiple sclerosis

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: ANU scientists crack DNA replication mystery

(Date:5/24/2013)... noise in one French Quarter neighborhood of New Orleans ... ordinances, Annette Hurley, PhD, Assistant Professor of Audiology at ... a third-year LSUHSC doctor of audiology student, recommend that ... health. Their case study is published online in the ... ., "An important part of an audiologist,s practice is ...
(Date:5/23/2013)... world,s most popular fruit, can be made both better-tasting ... varieties. , "Working with GM tomatoes that are ... a specific compound, allows us to pinpoint exactly how ... from the John Innes Centre. , The research could ... and shelf life characteristics because even higher levels of ...
(Date:5/23/2013)... suppresses lipid synthesis in the liver, UC Irvine endocrinologists ... liver diseases. , With this finding, Dr. Ellis ... in the field. Study results appear in the May ... , "The dogma in the steroid receptor field for ... the nucleus respond to steroid hormones by regulating genes ...
Breaking Biology News(10 mins):Please do try this at home 2The world's favorite fruit only better-tasting and longer-lasting 2UCI study reveals new mechanism for estrogen suppression of liver lipid synthesis 2
(Date:5/24/2013)... (PRWEB) May 24, 2013 Vestiage, ... lifestyle company focused on science-based research and development, ... anti-aging cosmeceuticals and nutraceuticals, announced today that it ... States for the sale of Reluma Skin Illuminating ... packet and application by sending an email to ...
(Date:5/23/2013)...  BioScrip, Inc. (NASDAQ: BIOS ) today ... 2013 Global Healthcare Conference to be held June 3-6, ... Richard Smith , President and Chief ... Chief Financial Officer, will present on Monday, June 3, ... About BioScrip BioScrip, Inc. provides comprehensive infusion ...
(Date:5/23/2013)... Ind. , May 23, 2013  Rahal Letterman ... in human cord blood stem cell banking and therapeutics, ... of the No. 16 Acorn Stairlifts Indy car driven ... for the remainder of the IZOD IndyCar 2013 season. ... (RLL) will work to support awareness of umbilical cord ...
(Date:5/23/2013)... PARK, Calif. , May 23, 2013 ... oral treatment for pain has reached an important milestone, ... trial of VBY-036 - a selective cathepsin S inhibitor. ... VBY-036 is a double-blind, randomized, placebo-controlled study designed to ... doses of VBY-036 in healthy adults. "The ...
Breaking Biology Technology:Vestiage Announces Launch of Exclusive Territories for Reluma Brand Sales in USA 2Vestiage Announces Launch of Exclusive Territories for Reluma Brand Sales in USA 3Vestiage Announces Launch of Exclusive Territories for Reluma Brand Sales in USA 4Vestiage Announces Launch of Exclusive Territories for Reluma Brand Sales in USA 5StemCyte, Inc. Joins Rahal Letterman Lanigan Racing As Associate Sponsor Of No. 16 IndyCar Program For James Jakes Beginning With The 97th Indianapolis 500 2StemCyte, Inc. Joins Rahal Letterman Lanigan Racing As Associate Sponsor Of No. 16 IndyCar Program For James Jakes Beginning With The 97th Indianapolis 500 3Virobay, Inc. initiates a Phase 1 Trial of VBY-036, a compound intended for the treatment of neuropathic pain 2Virobay, Inc. initiates a Phase 1 Trial of VBY-036, a compound intended for the treatment of neuropathic pain 3
Cached News: